Millennium Management’s Abeona Therapeutics ABEO Stock Holding History

Millennium Management’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.91M	Buy	425,426 +81,858	+24%	+$409K	﹤0.01%	3914
2025 Q4	$1.81M	Sell	343,568 -365,781	-52%	-$1.84M	﹤0.01%	4030
2025 Q3	$3.75M	Buy	709,349 +452,334	+176%	+$2.87M	﹤0.01%	3436
2025 Q2	$1.46M	Sell	257,015 -552,951	-68%	-$3.15M	﹤0.01%	4136
2025 Q1	$3.86M	Sell	809,966 -1,307,203	-62%	-$7.11M	﹤0.01%	3121
2024 Q4	$11.8M	Sell	2,117,169 -184,459	-8%	-$1.14M	0.01%	2026
2024 Q3	$14.5M	Sell	2,301,628 -375,023	-14%	-$1.96M	0.01%	1852
2024 Q2	$11.3M	Buy	2,676,651 +690,103	+35%	+$3.52M	0.01%	1975
2024 Q1	$14.4M	Buy	1,986,548 +567,873	+40%	+$3.6M	0.01%	1841
2023 Q4	$7.11M	Buy	1,418,675 +424,249	+43%	+$1.87M	﹤0.01%	2488
2023 Q3	$4.19M	Buy	994,426 +301,455	+44%	+$1.14M	﹤0.01%	2861
2023 Q2	$2.79M	Buy	692,971 +515,016	+289%	+$1.8M	﹤0.01%	3190
2023 Q1	$502K	Buy	177,955 +30,176	+20%	+$78.9K	﹤0.01%	4601
2022 Q4	$455K	Buy	+147,779	New	+$553K	﹤0.01%	4810
2022 Q3	–	Sell	-8,934	Closed	-$46K	–	7005
2022 Q2	$46K	Sell	8,934 -19,655	-69%	-$99.4K	﹤0.01%	6224
2022 Q1	$225K	Sell	28,589 -4,451	-13%	-$30.6K	﹤0.01%	5762
2021 Q4	$278K	Buy	33,040 +5,571	+20%	+$102K	﹤0.01%	5615
2021 Q3	$769K	Sell	27,469 -27,335	-50%	-$875K	﹤0.01%	4935
2021 Q2	$2.14M	Buy	+54,804	New	+$2.24M	﹤0.01%	3881
2021 Q1	–	Sell	-9,397	Closed	-$369K	–	5834
2020 Q4	$369K	Sell	9,397 -45,486	-83%	-$1.55M	﹤0.01%	4427
2020 Q3	$1.4K	Sell	54,883 -17,945	-25%	-$1.13M	﹤0.01%	2879
2020 Q2	$5.31M	Buy	72,828 +25,013	+52%	+$1.73M	0.01%	1713
2020 Q1	$2.51M	Sell	47,815 -75,459	-61%	-$5.04M	0.01%	1840
2019 Q4	$10.1M	Sell	123,274 -17,789	-13%	-$1.26M	0.01%	1370
2019 Q3	$7.97M	Buy	141,063 +3,129	+2%	+$234K	0.01%	1439
2019 Q2	$16.5M	Buy	137,934 +87,145	+172%	+$14.6M	0.02%	904
2019 Q1	$9.35M	Buy	50,789 +10,570	+26%	+$1.89M	0.01%	1315
2018 Q4	$7.18M	Buy	40,219 +13,150	+49%	+$2.87M	0.01%	1333
2018 Q3	$8.66M	Sell	27,069 -11,525	-30%	-$4.09M	0.01%	1414
2018 Q2	$15.4M	Buy	38,594 +1,944	+5%	+$849K	0.02%	1032
2018 Q1	$13.1M	Buy	36,650 +30,947	+543%	+$11.5M	0.02%	1155
2017 Q4	$2.26M	Sell	5,703 -3,798	-40%	-$1.57M	﹤0.01%	2206
2017 Q3	$4.05M	Buy	+9,501	New	+$2.55M	0.01%	1780
2017 Q2	–	Sell	-13,600	Closed	-$1.7M	–	3403
2017 Q1	$1.7M	Sell	13,600 -3,264	-19%	-$421K	﹤0.01%	2091
2016 Q4	$2.04M	Buy	16,864 +1,104	+7%	+$173K	﹤0.01%	1866
2016 Q3	$2.36M	Buy	15,760 +13,407	+570%	+$1.31M	﹤0.01%	1846
2016 Q2	$139K	Buy	+2,353	New	+$161K	﹤0.01%	2972
2015 Q4	–	Sell	-1,371	Closed	-$139K	–	3366
2015 Q3	$139K	Sell	1,371 -349	-20%	-$46.3K	﹤0.01%	3210
2015 Q2	$218K	Buy	1,720 +1,268	+281%	+$190K	﹤0.01%	3014
2015 Q1	$35K	Buy	+452	New	+$36.4K	﹤0.01%	3485

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management's ABEO Position: Q1 2026 in Review

Millennium Management increased its Abeona Therapeutics (ABEO) stake by 24% in Q1 2026, buying an estimated $409K and bringing the position to 425,426 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #3914.

Millennium Management first reported a position in ABEO in Q1 2015 and has held it in 40 quarters since. The position peaked at $16.5M in Q2 2019. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

Millennium Management held 425,426 shares of Abeona Therapeutics worth $1.91M as of Q1 2026.
Millennium Management bought 81,858 Abeona Therapeutics shares in Q1 2026, an estimated $409K.
Abeona Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3914 holding.
Millennium Management first reported a position in Abeona Therapeutics in Q1 2015 and has held it in 40 quarters since.
Millennium Management's Abeona Therapeutics position peaked at $16.5M in Q2 2019.
108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.